Cargando…
Estimated Costs and Long-term Outcomes of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System
IMPORTANCE: Management of high-risk non–muscle-invasive bladder cancer (NMIBC) represents a clinical challenge due to high failure rates despite prior bacillus Calmette-Guérin (BCG) therapy. OBJECTIVE: To describe real-world patient characteristics, long-term outcomes, and the economic burden in a p...
Autores principales: | Williams, Stephen B., Howard, Lauren E., Foster, Meagan L., Klaassen, Zachary, Sieluk, Jan, De Hoedt, Amanda M., Freedland, Stephen J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013821/ https://www.ncbi.nlm.nih.gov/pubmed/33787908 http://dx.doi.org/10.1001/jamanetworkopen.2021.3800 |
Ejemplares similares
-
Exposure to Agent Orange and Risk of Bladder Cancer Among US Veterans
por: Williams, Stephen B., et al.
Publicado: (2023) -
Bacillus Calmette-Guérin in the management of superficial bladder cancer
por: Kapoor, Rakesh, et al.
Publicado: (2008) -
Predictive biomarkers of response to bacillus Calmette‐Guérin immunotherapy and bacillus Calmette‐Guérin failure for non‐muscle invasive bladder cancer
por: Wang, Ziting, et al.
Publicado: (2022) -
Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
por: Guallar-Garrido, Sandra, et al.
Publicado: (2020) -
Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer
Publicado: (2021)